Aggressive Multimodality Therapy for Patients with Locally Advanced Esophageal Cancer: Is There a Role for Amifostine?

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Most patients with locally advanced esophageal cancer die from their disease, despite complete surgical extirpation of tumor or institution of aggressive, multimodality treatment. Nevertheless, a favorable trend emerging in the management of such patients is that "more therapy is better." This review describes several studies indicating that aggressive, combined-modality therapy provides a survival advantage for patients with locally advanced esophageal cancer. An ongoing North Central Cancer Treatment Group trial further capitalizes on the concept of "more is better," and tests subcutaneous amifostine (Ethyol, WR-2721; MedImmune, Inc, Gaithersburg, MD) to balance the need for aggressive therapy with the need to mitigate associated toxicity.

Original languageEnglish (US)
Pages (from-to)72-75
Number of pages4
JournalSeminars in oncology
Volume30
Issue number6 SUPPL. 18
DOIs
StatePublished - Dec 2003

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Aggressive Multimodality Therapy for Patients with Locally Advanced Esophageal Cancer: Is There a Role for Amifostine?'. Together they form a unique fingerprint.

  • Cite this